De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Immix Biopharma Beheer

Beheer criteriumcontroles 3/4

De CEO Immix Biopharma's is Ilya Rachman, benoemd in Jan2012, heeft een ambtstermijn van 12.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.13M, bestaande uit 39.5% salaris en 60.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.14% van de aandelen van het bedrijf, ter waarde $ 1.69M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 3.5 jaar.

Belangrijke informatie

Ilya Rachman

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	39.5%
Dienstverband CEO	12.8yrs
Eigendom CEO	4.1%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	3.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ilya Rachman's beloning veranderd ten opzichte van Immix Biopharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$19m
Mar 31 2024	n/a	n/a	-US$18m
Dec 31 2023	US$1m	US$446k	-US$15m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$2m	US$425k	-US$8m
Sep 30 2022	n/a	n/a	-US$27m
Jun 30 2022	n/a	n/a	-US$26m
Mar 31 2022	n/a	n/a	-US$25m
Dec 31 2021	US$397k	US$193k	-US$24m

Compensatie versus markt: De totale vergoeding ($USD 1.13M ) Ilya } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Ilya is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ilya Rachman (51 yo)

12.8yrs

Tenure

US$1,129,881

Compensatie

Dr. Ilya Rachman, MD, PhD, MBA, Co-Founder, Chairman and Chief Executive Officer at Immix Biopharma, Inc since 2012. Dr. Rachman is a pioneering physician/scientist, cell biologist and among the first to f...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ilya Rachman	Co-Founder	12.8yrs	US$1.13m	4.14% $ 1.5m
Gabriel Morris	CFO & Director	3.6yrs	US$1.13m	1.04% $ 383.0k
Graham Ross	Chief Medical Officer & Head of Clinical Development	3.3yrs	US$104.42k	0% $ 0
Sean Senn	Co-Founder	no data	geen gegevens	3.28% $ 1.2m
Vladimir Torchilin	Scientific Co-Founder	12.8yrs	geen gegevens	3.3% $ 1.2m
Nandan Oza	Head of Chemistry	7.4yrs	geen gegevens	geen gegevens
David Marks	Chief Medical Officer of Cell Therapy	1.8yrs	geen gegevens	geen gegevens
Gerhard Bauer	Head of Cell Therapy Manufacturing	1.8yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IMMX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ilya Rachman	Co-Founder	12.8yrs	US$1.13m	4.14% $ 1.5m
Gabriel Morris	CFO & Director	3.6yrs	US$1.13m	1.04% $ 383.0k
Jane Buchan	Independent Director	3.3yrs	US$173.63k	0.082% $ 30.1k
George Sledge	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gary Schiller	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Larry Norton	Chair of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jason Hsu	Independent Director	11.8yrs	US$156.38k	3.26% $ 1.2m
Magda Marquet	Independent Director	3.3yrs	US$180.64k	0.17% $ 61.8k
Helen Adams	Lead Independent Director	3.3yrs	US$429.37k	0.64% $ 234.2k
Carey Ng	Independent Director	4.9yrs	US$159.88k	0.073% $ 26.8k
Razelle Kurzrock	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Galit Lahav	Member of Scientific Advisory Board	3.2yrs	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IMMX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Immix Biopharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Immix Biopharma Announces Raymond Comenzo Joins Scientific Advisory Board of Nexcella Scientific Advisory

Independent Director recently bought US$52k worth of stock

Insufficient new directors

Immix Biopharma, Inc., Annual General Meeting, Jun 11, 2024

Director recently bought US$267k worth of stock

Director recently bought US$200k worth of stock

Recent updates

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Raymond Comenzo Joins Scientific Advisory Board of Nexcella Scientific Advisory

Immix Biopharma, Inc. Announces the Addition of Three Additional Clinical Trial Sites for Its U.S. Relapsed/Refractory Al Amyloidosis Clinical Trial NEXICART-2

Independent Director recently bought US$52k worth of stock

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma, Inc. Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Insufficient new directors

New major risk - Revenue and earnings growth

Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation

Immix Biopharma, Inc., Annual General Meeting, Jun 11, 2024

Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial

New major risk - Shareholder dilution

Immix Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $14.999999 million.

New minor risk - Market cap size

Director recently bought US$267k worth of stock

Immix Biopharma, Inc. Announces New Clinical Data from Its Phase 1b/2a NEXICART-1

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

New major risk - Financial position

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Director recently bought US$200k worth of stock

Immix Biopharma, Inc Announces U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Immix Biopharma, Inc. Appoints Yekaterina Chudnovsky as Member of the Board

Immix Biopharma, Inc. Reports 2Nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1B/2A Imx-110 Imx-110 Clinical Trial

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer

Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX 110 in Advanced Solid Tumors

Immix Biopharma Announces Patient Dosing in Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Releases and Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

High number of new directors

Immix Biopharma, Inc. Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial

Immixbio Approves 4 Additional Clinical Trial Sites for Imx-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans

Immix Biopharma, Inc. Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

Immix Biopharma, Inc. Announces Positive Interim Study Data Showing That After One Cycle of Treatment, Immixbio's Lead Candidate IMX-110 Produces 75% Survival Vs. 0% Survival for Trabectedin

We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely

High number of new and inexperienced directors

Immix Biopharma, Inc., Annual General Meeting, Jun 08, 2022

Immix Biopharma, Inc. Initiates Good Manufacturing Practice Manufacturing of IMX-120

Immix Biopharma, Inc. Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles

Immix Biopharma, Inc IMX-110 Produces 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

U.S. Food and Drug Administration Approves Immix Biopharma, Inc. Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

High number of new and inexperienced directors

Immix Biopharma, Inc. has completed an IPO in the amount of $21 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd